MNT 002
Alternative Names: MNT-002Latest Information Update: 18 Apr 2024
At a glance
- Originator Minotaur Therapeutics
- Class Anti-inflammatories; Antibodies; Peptides; Recombinant fusion proteins
- Mechanism of Action Kv1.3 potassium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Autoimmune disorders; Inflammation
Most Recent Events
- 18 Apr 2024 MNT 002 is available for licensing as of 18 Apr 2024. https://minotaurtherapeutics.com/?page_id=87 (Minotaur Therapeutics pipeline, April 2024)
- 18 Apr 2024 Preclinical trials in Autoimmune disorders in USA (Parenteral) prior to April 2024 (Minotaur Therapeutics pipeline, April 2024)
- 18 Apr 2024 Preclinical trials in Inflammation in USA (Parenteral) prior to April 2024 (Minotaur Therapeutics pipeline, April 2024)